Drugs / GSK2256098
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02551653 | Nov 2015 → Mar 2017 | pulmonary arterial hypertension | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01938443 | Nov 2013 → Jun 2016 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01138033 | Jul 2010 → Dec 2015 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00996671 | Nov 2009 → Mar 2010 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02428270 | Apr 2016 → Jun 2017 | adenocarcinoma, malignant pancreatic neoplasm | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT02523014 | Sep 2015 → Jan 2027 expected | NF2-related schwannomatosis, intracranial meningioma | Alliance for Clinical Trials in Oncology | Recruiting | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2256098 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01138033 ↗ |
| Action | Inhibit | “Focal adhesion kinase 1 inhibitor” CHEMBL4742157 ↗1“focal adhesion kinase inhibitor” NCT00996671 ↗ |
| Modality | Small molecule | — CHEMBL4742157 ↗ |
| Route | Oral | “following Single Oral Doses of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Healthy Subjects” NCT00996671 ↗ |
| Target | PTK2 | “Focal adhesion kinase 1 inhibitor” CHEMBL4742157 ↗ |